Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in The Netherlands (3DUTCH)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms 3DUTCH
- Sponsors AbbVie
- 07 Sep 2017 Planned End Date changed from 31 May 2018 to 1 Sep 2018.
- 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2016 New trial record